$62.83 +0.01 (%) AbbVie Inc - New York Stock Exchange, Inc.

Sep. 30, 2016 | 11:10 AM

Partner Headlines

  1. Rayno 2016 Life Science Portfolio Update

    TalkMarkets | Sep. 29, 2016 | 21:14PM EST
  2. Gilead 'Paralyzed' On Likely Hepatitis C Share Loss To AbbVie, Merck

    IBD | Sep. 27, 2016 | 16:28PM EST
  3. Biosimilars In Limelight On FDA Approval Of Amgen Drug

    TalkMarkets | Sep. 27, 2016 | 13:30PM EST
  4. How Will Healthcare Stocks Be Affected If Donald Trump Wins?

    Dividend.com | Sep. 12, 2016 | 12:00PM EST
  5. Don’t Worry, AbbVie Will Be Just Fine

    Dividend.com | Aug. 31, 2016 | 09:00AM EST
  6. Apple, Facebook, Alphabet, Amazon, Ford, McDonald's Headline Busy Week

    Investors Business Daily | Jul. 29, 2016 | 12:13PM EST
  7. Trending on Dividend.com: Technology Stocks Gain Visibility as Earnings Season Is Underway

    Dividend.com | Jul. 29, 2016 | 12:00PM EST
  8. AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags

    Investors Business Daily | Jul. 29, 2016 | 10:46AM EST
  9. Exxon, Chevron, Merck Earnings, Q2 GDP Data On Tap Friday

    Investors Business Daily | Jul. 28, 2016 | 17:21PM EST
  10. Investing Action Plan: Apple, Facebook, Amazon, Big Oil, Boeing, Fed

    Investors Business Daily | Jul. 23, 2016 | 08:00AM EST
  11. 5 Big Drugmakers Reporting Earnings Next Week

    Investors Business Daily | Jul. 22, 2016 | 13:57PM EST
  12. John Paulson Bulks Up Health Care Bet

    GuruFocus | Feb. 17, 2016 | 17:02PM EST
  13. Gilead, Johnson & Johnson or Roche?

    GuruFocus | Feb. 11, 2016 | 12:15PM EST
  14. IPO Indexes Weak, But A Few Leaders Outperform

    IBD | Feb. 10, 2016 | 16:42PM EST
  15. The Generic Drug Battle

    Benzinga | Feb. 10, 2016 | 09:13AM EST
  16. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

    Benzinga | Feb. 8, 2016 | 15:27PM EST
  17. Benzinga's Top Initiations

    Benzinga | Feb. 5, 2016 | 09:32AM EST
  18. Is Big Pharma Hinting At A SMID-Cap Biotech Rally?

    Benzinga | Feb. 3, 2016 | 13:16PM EST
  19. Earnings Recap For January 29

    Benzinga | Jan. 29, 2016 | 17:36PM EST
  20. Biogen Drug 'Increasingly Vulnerable,' Analyst Warns After Speaking With MS Expert

    Benzinga | Jan. 29, 2016 | 09:29AM EST
  21. AbbVie Falling After Q4 Report, 2016 Guidance Affirmation

    Benzinga | Jan. 29, 2016 | 08:14AM EST
  22. Earnings Scheduled For January 29, 2016

    Benzinga | Jan. 29, 2016 | 04:05AM EST
  23. Abbvie Announces Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA

    Benzinga | Jan. 28, 2016 | 04:29AM EST
  24. US Big Pharma: What To Watch For In Q4 Results

    Benzinga | Jan. 25, 2016 | 11:16AM EST
  25. Barron's 2016 Roundtable Part 2: Lots Of Savvy Investment Ideas

    Benzinga | Jan. 24, 2016 | 17:05PM EST
  26. Halozyme Confirms $5 Million Milestone Payment From AbbVie

    Benzinga | Jan. 21, 2016 | 14:54PM EST
  27. Alphabet, Apple In Tech Health Care 'Convergence'

    IBD | Jan. 21, 2016 | 08:02AM EST
  28. 11 Different Ways To Play The Bear Market (From 11 Traders)

    Benzinga | Jan. 14, 2016 | 14:38PM EST
  29. Lee Ainslie Gains From Liberty Global But Loses From Axiall

    GuruFocus | Jan. 13, 2016 | 12:01PM EST
  30. Roche

    IBD | Jan. 12, 2016 | 18:41PM EST
  31. AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen

    Benzinga | Jan. 11, 2016 | 07:02AM EST
  32. Mylan, Momenta Team Up To Develop Biosimilar Drugs

    IBD | Jan. 8, 2016 | 15:34PM EST
  33. 3 Potential Blockbuster Drugs Launching in 2016

    IBD | Jan. 6, 2016 | 09:42AM EST
  34. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD | Dec. 30, 2015 | 14:16PM EST
  35. 10 Undervalued Dividend Champions for 2016: Be Greedy When Others Are Fearful

    GuruFocus | Dec. 24, 2015 | 16:37PM EST
  36. Express Scripts Gets Mixed Reviews After '16 Guidance

    IBD | Dec. 22, 2015 | 12:41PM EST
  37. Gilead Buys Into Galapagos Drug That AbbVie Ditched

    IBD | Dec. 17, 2015 | 14:01PM EST
  38. Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds

    Benzinga | Dec. 12, 2015 | 14:05PM EST
  39. Benzinga's Top Upgrades

    Benzinga | Dec. 7, 2015 | 08:59AM EST
  40. IMBRUVICA® (Ibrutinib) Phase 3 RAY Data Show Significant Reductions in Disease Progression versus Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma Patients

    Benzinga | Dec. 7, 2015 | 08:31AM EST
  41. AbbVie Announces NEJM Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia

    Benzinga | Dec. 6, 2015 | 19:15PM EST
  42. AbbVie Announces Ibrutinib Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma

    Benzinga | Dec. 6, 2015 | 18:58PM EST
  43. AbbVie Reports Phase 2 Results of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion, Achived Primary Endpoint With 79.4% ORR

    Benzinga | Dec. 6, 2015 | 11:10AM EST
  44. Weekend Watch: Yahoo's Fate, Blood Cancer Fighters

    IBD | Dec. 5, 2015 | 08:02AM EST
  45. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD | Dec. 4, 2015 | 13:46PM EST
  46. Merger Landscape Still Inviting To Inversions

    Benzinga | Dec. 2, 2015 | 20:18PM EST
  47. Blood-Cancer Fighters To Strut Their Stuff At ASH

    IBD | Dec. 2, 2015 | 08:02AM EST
  48. Gilead's HCV Pricing Policy Slammed By Senate Report

    IBD | Dec. 1, 2015 | 16:11PM EST
  49. 3 Big Pharma Upgrades (And One Downgrade) At Barclays

    IBD | Dec. 1, 2015 | 15:31PM EST
  50. Barclays' Biopharmaceuticals Blueprint For 2016

    Benzinga | Dec. 1, 2015 | 11:54AM EST
Trading Center